A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Required: KRAS G12C mutation

Documentation of the presence of a KRAS G12C mutation

Required: PD-L1 (CD274) expression status known (status known)

Documentation of known PD-L1 expression status in tumor tissue

Cannot have received: KRAS G12C inhibitor

Prior treatment with KRAS G12C inhibitors

Cannot have received: pan-KRAS/RAS inhibitor

Prior treatment with ... pan-KRAS/RAS inhibitors

Cannot have received: systemic therapy

Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization

Cannot have received: radiation therapy

Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung >30Gy within 6 months prior to randomization

Cannot have received: immune checkpoint inhibitor

Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors

Cannot have received: allogeneic stem cell or solid organ transplantation

Prior allogeneic stem cell or solid organ transplantation